The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC).
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Moderna.Inc; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Accent Therapeutics; Alentis Therapeutics; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; Lilly; Menarini; Merus; MSD; Novartis; Ono Pharmaceutical; Peptomyc; Pfizer; Pierre Fabre; Quantro Therapeutics; Scandion Oncology; Scorpion Therapeutics; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO
 
Clélia Coutzac
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Merck Serono; MSD Oncology; SERVIER
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; SERVIER
Speakers' Bureau - Amgen; Merck Serono; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Mundipharma; Sandoz; SERVIER
 
Christelle De La Fouchardiere
Consulting or Advisory Role - Amgen; Astellas Pharma; BeiGene; Bristol-Myers Squibb; Daichi-Sankyo; Gilead Sciences; Jazz Pharmaceuticals; MSD Oncology; Pierre Fabre; Roche/Genentech; SERVIER; Takeda
Research Funding - Agenus (Inst); MSD (Inst); Pierre Fabre (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD Oncology; Pierre Fabre; SERVIER
 
Jeeyun Lee
Consulting or Advisory Role - AstraZeneca; Guardant Health AMEA; Mirati Therapeutics; Oncologie; Trutino Biosciences
Research Funding - AstraZeneca; Merck Sharp & Dohme
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
Yoon-Koo Kang
Consulting or Advisory Role - DAEHWA Pharmaceutical; HLB
 
Philip Fanning
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
Travel, Accommodations, Expenses - ALX Oncology
 
Grace An
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
 
Feng Jin
Employment - Theravance
Consulting or Advisory Role - Alx oncology
 
Alison Forgie
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology, Pfizer
Patents, Royalties, Other Intellectual Property - Patent assignee: Rinat Neuroscience
 
Jaume Pons
Employment - ALX Oncology
Leadership - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
Patents, Royalties, Other Intellectual Property - ALX Oncology
 
Athanasios Tsiatis
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
Patents, Royalties, Other Intellectual Property - ALX Oncology (Inst); Genomic Health-Proprietary (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - ALX Oncology
 
Sophia Randolph
Employment - ALX Oncology
Stock and Other Ownership Interests - Carrick Therapeutics; Pfizer
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Daiichi Sankyo; Merck KGaA; Sanofi/Aventis
Consulting or Advisory Role - Abbvie; Astellas Pharma; Daiichi Sankyo; Metafines; MSD
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Elevar Therapeutics (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genome & Company (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IgM Biosciences (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Jazz Pharmaceuticals (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Medicenna (Inst); MedPacto (Inst); Merck KGaA (Inst); Metafines (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Panolos Bioscience (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); TRIO Oncology (Inst); Trishula Therapeutics (Inst); Wellmarker Bio (Inst); Y-BIOLOGICS (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology